Studying Lung Damage That Can Follow Tuberculosis in Adults
Follows adults with pulmonary tuberculosis to track lung damage that can remain afterward.
Plain-language title generated from the registry record
Registry title: Risk Factors and Biomarkers for Post-tuberculosis Lung Damage
Key facts
- Where
- Beijing, ChinaSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 60 years old?
Source: NCT05426720, who can take part
Where in China
- Beijing Geriatric HospitalBeijing, ChinaTaking people
- Peking University Third HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking University Third Hospital
- Trial code
- NCT05426720
- Record updated
- 22 June 2022
- Original description
This prospective study aims to determine the incidence of Post-tuberculosis lung damage (PTLD), examine trends in the changes in lung function, and investigate the impact of smoking and other factors on respiratory symptoms, lung function, and chest CT findings, which will aid in the development of prognostic and therapeutic strategies for PTLD.Read full original descriptionShow less
Risk Factors and Biomarkers for Post-tuberculosis Lung Damage in a Chinese Cohort: Protocol for a Prospective Observational Study
This prospective study aims to determine the incidence of Post-tuberculosis lung damage (PTLD), examine trends in the changes in lung function, and investigate the impact of smoking and other factors on respiratory symptoms, lung function, and chest CT findings, which will aid in the development of prognostic and therapeutic strategies for PTLD.
Inclusion: Male patients aged 25-60 years newly diagnosed with active pulmonary TB.
Exclusion: patients infected with multidrug-resistant TB; patients with malignant neoplasms (e.g., lung cancer) or severe cardiovascular and cerebrovascular diseases; patients with positive sputum smear or TB culture results; human immunodeficiency virus-positive patients; non-compliant patients who were unable to complete the lung function tests; patients without lung parenchymal destruction (such as tuberculous pleurisy). -.